Reimbursed with a limitationOriginator productATC L01EC03

Braftovi

Braftovi is an originator product from Pierre Fabre Pharma AG and is listed on the FOPH Specialities List. Swiss mandatory health insurance therefore reimburses it within the authorised indication. The public price ranges from CHF 629.75 to CHF 5'464.95 depending on the pack; the patient co-payment is 10 per cent plus the deductible.

Core data

Authorisation holder
Pierre Fabre Pharma AG
ATC code
L01EC03
IT group
07.16.10 Cytostatica
Active substances
Encorafenibum
Preparation type
Originator product
On the SL since
01/12/2019
Last price change
01/04/2024
Co-payment
10%

Prices per pack

The ex-factory price is the authorisation holder's price; the public price adds the distribution share and VAT. Both are FOPH maximum prices: nothing above them may be charged.

Braftovi Price table As of 17/09/2026
Dosage formPack sizeEx-factory pricePublic priceValid fromCat.GTIN
Kaps 50 mgBlist 28 StkCHF 563.97CHF 629.7501/04/2024A7680667950011
Kaps 75 mgBlist 42 StkCHF 1'256.61CHF 1'383.0501/04/2024A7680667950028
Kaps 75 mgBlist 168 StkCHF 5'026.44CHF 5'464.9501/04/2024A7680667950042

Limitation

This preparation is reimbursed only under the conditions below. The text is the binding FOPH wording; outside those conditions basic insurance does not pay.

The FOPH publishes limitation texts in German, French and Italian only. The German wording is reproduced verbatim below.

FOPH wordingIndication 20874.01Valid from 01/04/2024

Wird nur in Kombination mit MEKTOVI zur Behandlung von erwachsenen Patienten mit nicht-resezierbarem oder metastasiertem Melanom mit einer BRAF-V600-Mutation vergütet.
Die Therapie wird nur bis zur Progression der Krankheit vergütet.
Die Behandlung bedarf der Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes.

Die Pierre Fabre Pharma AG erstattet nach Aufforderung durch denjenigen Krankenversicherer, bei dem die versicherte Person zum Zeitpunkt des Bezugs versichert war, auf die Kombination von BRAFTOVI und MEKTOVI für jede bezogene MEKTOVI Packung (=Indikator für einen Behandlungszyklus) 24.49% des Fabrikabgabepreises zurück. Die Mehrwertsteuer kann nicht zusätzlich zu diesem Anteil des Fabrikabgabepreises zurückgefordert werden. Die Aufforderung zur Rückvergütung soll ab dem Zeitpunkt der Verabreichung erfolgen.

Folgender Indikationscode ist an den Krankenversicherer zu übermitteln: 20874.01

FAQ

Is Braftovi covered by Swiss health insurance?

Yes, but only under conditions. Braftovi is on the Specialities List with a limitation: basic insurance reimburses it only when the conditions in the limitation text are met, in some cases only after the insurer has granted cost approval.

What does Braftovi cost in Switzerland?

The public price is the maximum price set by the FOPH and for Braftovi ranges from CHF 629.75 to CHF 5'464.95 per pack. The ex-factory price ranges from CHF 563.97 to CHF 5'026.44. Pharmacies may not charge more, but may charge less.

Correct or complete this entry

Market access

Do you need your product on the Specialities List?

Questions about SL listing, prices or limitations? Contact Swiss Reimbursement.

  • Independent directory
  • Official FOPH data
  • Website in eight languages
Send an enquiry
Contact

About 2 minutes. No obligation.

First, a little about your business.

Your answers stay in this page until you send your enquiry.

What would you like to achieve?

Your project

Where can we reach you?

You can go back to review your answers before sending.

* Required fields
Prefer email? info@swissreimbursement.com